Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Dusan Harmacek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Abatacept, Graft Rejection, Graft Survival, Kidney Transplantation. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Calcineurin inhibitor (CNI) nephrotoxicity drives long‐term kidney‐function decline after simultaneous pancreas‐kidney (SPK) and liver‐kidney (LK) transplantation, but belatacept conversion, as an alternative strategy, is poorly studied in these recipients, whose non‐kidney allograft rejection risk differs.
Methods
We retrospectively studied six SPK and six LK recipients converted from CNI‐ to belatacept‐based immunosuppression and analyzed the cohorts separately alongside a narrative review of published SPK/LK conversion experiences. Outcomes were estimated glomerular filtration rate (eGFR) trajectories and slopes, donor‐specific antibodies (DSA) and rejection, pancreatic, hepatic and metabolic parameters, infections, and survival, reported descriptively with exploratory estimates and 95% confidence intervals (CI).
Results
Conversion occurred a median of 64 (SPK) and 89 (LK) months after transplantation, always with a transient low‐dose CNI overlap (target trough 3‐4 ng/ml). In SPK recipients, median eGFR rose from 45.4 to 55.5 mL/min/1.73m 2 and the median eGFR slope changed from −3.9 to +5.6 mL/min/year (mixed‐model slope change +12.6, 95% CI 2.9 to 22.3); in LK recipients, from 38.8 to 46.3 and from −3.1 to +4.1 (estimate +6.3, 95% CI −4.2 to 16.7). No new DSA developed; pre‐existing DSA declined or remained stable. Pancreatic and liver function stayed stable. Two infections in LK recipients ( Pneumocystis pneumonia, adenovirus) were possibly belatacept‐aggravated. Over a median 25 months, 8/12 (67%) remained on belatacept.
Conclusions
Late belatacept conversion with a transient low‐dose CNI overlap was feasible in selected SPK and LK recipients and was associated with stable‐to‐improved kidney function without a pancreatic or hepatic safety signal. The uncontrolled design supports feasibility, not efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
- Division of Nephrology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
- Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Zitieren
APA
Harmacek, D., Rho, E., von Moos, S., Simmler, S., Welte, T., Rössler, F., Schachtner, T., & Weidmann, L. (2026). Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review. Clinical Transplantation. https://doi.org/10.1111/ctr.70719
Vancouver
Harmacek D, Rho E, von Moos S, Simmler S, Welte T, Rössler F, et al. Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review. Clinical Transplantation. 2026. doi:10.1111/ctr.70719
BibTeX
@article{Harmacek2026,
author = {Harmacek, Dusan and Rho, Elena and von Moos, Seraina and Simmler, Severin and Welte, Thomas and Rössler, Fabian and Schachtner, Thomas and Weidmann, Lukas},
title = {Belatacept Conversion in Simultaneous Pancreas‐Kidney and Liver‐Kidney Transplant Recipients: A Single‐Center Feasibility Cohort and Narrative Review},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70719}
}
EUVIMED